Baseline characteristics

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting · Source last updated 2014-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      308

   2. group Id

      BG001

      value

      104

   3. group Id

      BG002

      value

      412

   units

   Participants

groups

1. description

   Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle Netupitant and Palonosetron Dexamethasone

   id

   BG000

   title

   Netupitant and Palonosetron Plus Dexamethasone

2. description

   Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle. Aprepitant Palonosetron Dexamethasone

   id

   BG001

   title

   Aprepitant and Palonosetron Plus Dexamethasone

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            10.44

            value

            56.5

         2. group Id

            BG001

            spread

            11.70

            value

            56.9

         3. group Id

            BG002

            spread

            10.76

            value

            56.6

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            155

         2. group Id

            BG001

            value

            51

         3. group Id

            BG002

            value

            206

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            153

         2. group Id

            BG001

            value

            53

         3. group Id

            BG002

            value

            206

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            258

         2. group Id

            BG001

            value

            87

         3. group Id

            BG002

            value

            345

      title

      White

   2. categories

      1. measurements

         1. group Id

            BG000

            value

            3

         2. group Id

            BG001

            value

            0

         3. group Id

            BG002

            value

            3

      title

      Black

   3. categories

      1. measurements

         1. group Id

            BG000

            value

            47

         2. group Id

            BG001

            value

            17

         3. group Id

            BG002

            value

            64

      title

      Asian

   param Type

   NUMBER

   title

   Race/Ethnicity, Customized

   unit Of Measure

   participants

population Description

Safety Population, i.e. patients receiving study drugs (either netupitant/palonosetron combination or aprepitant/palonosetron regimen, both with dexamethasone)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice